HomeBUSINESS
BUSINESS

Mitsubishi Tanabe Chief Looks to Tap Canaglu’s CV Outcome Data to Boost Sales
(Aug.30.2017)

Mitsubishi Tanabe President Masayuki Mitsuka
Mitsubishi Tanabe Pharma is set to draw on the cardiovascular reduction data that came out earlier this year for its sodium glucose co-transporter-2 (SGLT-2) inhibitor Canaglu (canagliflozin) to achieve its sales target of 100 billion yen in the area of diabetes and nephrology in the future ...
(LOG IN FOR FULL STORY)

News Calendar